{
    "clinical_study": {
        "@rank": "30001", 
        "acronym": "B1971042", 
        "arm_group": {
            "arm_group_label": "rLP2086", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This study will assess the safety, tolerability and immunogenicity of bivalent rLP2086\n      vaccine in laboratory workers \u226518 to \u226465 years of age administered on a Month 0, 2, and 6\n      schedule. The study will recruit laboratory personnel (inclusive of Pfizer staff) who work\n      directly with pathogenic Neisseria meningitidis in the context of the bivalent rLP2086\n      vaccine development program.  The study will provide descriptive safety and immunogenicity\n      data following vaccination of these individuals with bivalent rLP2086 vaccine."
        }, 
        "brief_title": "Study To Describe The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine In Laboratory Workers \u226518 To \u226465 Years Of Age", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "condition": "Meningitis, Meningococcal, Serogroup B", 
        "condition_browse": {
            "mesh_term": [
                "Meningitis", 
                "Meningitis, Meningococcal"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Laboratory personnel (inclusive of Pfizer staff) who work directly with pathogenic\n             Neisseria meningitidis in the context of the bivalent rLP2086 vaccine development\n             program.\n\n          2. Male or female subject aged \u226518 to \u226465 years at the time of enrollment.\n\n          3. Negative urine pregnancy test.\n\n        Exclusion Criteria:\n\n          1. Subjects receiving any allergen immunotherapy with a nonlicensed product or receiving\n             allergen immunotherapy with a licensed product and are not on stable maintenance\n             doses.\n\n          2. A known or suspected defect of the immune system that would prevent an immune\n             response to the vaccine, such as subjects with congenital or acquired defects in B\n             cell function or those receiving immunosuppressive therapy.  Subjects with terminal\n             complement deficiency are excluded from participation in this study.\n\n          3. Significant neurological disorder or history of seizure (excluding simple febrile\n             seizure).\n\n          4. Current chronic use of systemic antibiotics.\n\n          5. Received any investigational drugs, vaccines, or devices within 28 days before\n             administration of the first study vaccination.\n\n          6. Any neuroinflammatory or autoimmune condition, including, but not limited to,\n             transverse myelitis, uveitis, optic neuritis, and multiple sclerosis.\n\n          7. Prior receipt of any vaccine specifically targeting fHBP or LP2086 antigens.\n\n          8. History of microbiologically proven disease caused by Neisseria meningitidis."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "13", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01768117", 
            "org_study_id": "B1971042"
        }, 
        "intervention": {
            "arm_group_label": "rLP2086", 
            "description": "0.5 ml intramuscular injection of 120 microgram bivalent rLP2085 administered at 0, 2 and 6 months", 
            "intervention_name": "rLP2086", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 17, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1971042&StudyName=Study%20To%20Describe%20The%20Safety%2C%20Tolerability%2C%20And%20Immunogenicity%20Of%20Bivalent%20Rlp2086%20Vaccine%20In%20Laboratory%20Workers%20%u226518%20To%20%u226465%20"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Hackensack", 
                    "country": "United States", 
                    "state": "New Jersey", 
                    "zip": "07601"
                }, 
                "name": "Pfizer Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Single-Arm, Open-Label Study To Describe The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine In Laboratory Workers \u226518 To \u226465 Years Of Age", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Proportion of subjects with titer \u2265 lower limit of quantitation (LLOQ) for each of the 4 primary test strains at 1 month after the third vaccination with bivalent rLP2086 vaccine.", 
                "safety_issue": "No", 
                "time_frame": "7 Months"
            }, 
            {
                "measure": "Percentage of subjects reporting local reactions and systemic events for 7 days after each vaccination visit.", 
                "safety_issue": "Yes", 
                "time_frame": "6 Months"
            }, 
            {
                "measure": "Percentage of subjects reporting the use of antipyrectic medication for 7 days after each vaccination visit", 
                "safety_issue": "Yes", 
                "time_frame": "6 Months"
            }, 
            {
                "measure": "Percentage of subjects with at least 1 SAE 30 days after each vaccination, 30 days after any vaccination, during the vaccination phase, during the follow-up phase, and throughout the study period.", 
                "safety_issue": "Yes", 
                "time_frame": "12 Months"
            }, 
            {
                "measure": "Percentage of subjects with at least 1 medically attended adverse event 30 days after each vaccination, 30 days after any vaccination, during the vaccination phase, during the follow-up phase, and throughout the study period.", 
                "safety_issue": "Yes", 
                "time_frame": "12 Months"
            }, 
            {
                "measure": "Percentage of subjects with at least 1 newly diagnosed chronic medical condition 30 days after each vaccination, 30 days after any vaccination, during the vaccination phase, during the follow-up phase, and throughout the study period.", 
                "safety_issue": "Yes", 
                "time_frame": "12 Months"
            }, 
            {
                "measure": "Percentage of subjects with at least 1 adverse event 30 days after each vaccination, 30 days after any vaccination and during the vaccination phase.", 
                "safety_issue": "Yes", 
                "time_frame": "12 Months"
            }, 
            {
                "measure": "Percentage of subjects reporting at least 1 immediate AE after each vaccination.", 
                "safety_issue": "Yes", 
                "time_frame": "6 Months"
            }, 
            {
                "measure": "Subject's days missing school or work due to AEs during the vaccination phase", 
                "safety_issue": "Yes", 
                "time_frame": "7 Months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01768117"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Proportion of subjects with a titer \u2265 lower limit of quantitation for each of the 4 primary test strains 1 month after the first vaccination with bivalent rLP2086 vaccine.", 
                "safety_issue": "No", 
                "time_frame": "1 Month"
            }, 
            {
                "measure": "Proportion of subjects with a titer \u2265 lower limit of quantitation for each of the 4 primary test strains 1 month after the second vaccination with bivalent rLP2086 vaccine.", 
                "safety_issue": "No", 
                "time_frame": "4 Months"
            }, 
            {
                "measure": "Proportion of subjects with a titer \u2265 lower limit of quantitation for each of the 4 primary test strains immediately prior to the third vaccination with bivalent rLP2086 vaccine.", 
                "safety_issue": "No", 
                "time_frame": "6 Months"
            }, 
            {
                "measure": "Proportion of subjects achieving an hSBA titer \u2265 lower limit of quantitation (LLOQ) for all 4 primary test strains combined, 1 month after the third vaccination with bivalent rLP2086 vaccine", 
                "safety_issue": "No", 
                "time_frame": "7 Months"
            }, 
            {
                "measure": "Proportion of subjects achieving at least a 4-fold increase in hSBA titer from baseline to 1 month after the third vaccination with bivalent rLP2086 vaccine for each of the 4 primary test strains", 
                "safety_issue": "No", 
                "time_frame": "7 Months"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}